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ABSTRACT
This study investigated the efficacy of a commercial enzyme immunoassay (Directigen RSV, ColorPAC) in
comparisonwith the shell vial culturemethod (usingHep-2 cells) for the detection of respiratory syncytial
virus (RSV) in nasopharyngeal aspirates from children with bronchiolitis. During the period 1995–2002,
4950 samples were examined. RSV was detected in 1660 (33.5%) samples, with a sensitivity of 80.9%, a
specificity of 97.5%, a positive predictive value of 93.8%, a negative predictive value of 91.6%, and a
testing efficiency value of 92.2% compared with shell vial culture. In 83 (5%) samples, the ColorPACwas
positive and the shell vial assay was negative. Of these, 71 (85.6%) were false-negative by cell culture. The
true false-positive results obtained by ColorPAC represented only 0.7% of all RSV-positive samples. In
general, no statistically significant differences were detected between the different months and epidemic
periods studied. Comparedwith ColorPAC, the shell vial culture method displayed a sensitivity of 95.8%
and a specificity of 100%. Overall, the ColorPAC assay was an acceptable, simple and rapid method for
the antigenic detection of RSV in paediatric respiratory samples.
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INTRODUCTION
Respiratory syncytial virus (RSV) is recognised as
the principal causative agent of acute lower
respiratory tract infections affecting infants and
young children aged < 2 years. Most infections
occur during annual epidemic outbreaks in
winter and early spring. In the hospital setting,
RSV is transmitted efficiently from patient to
patient in the absence of appropriate infection
control measures [1,2]. Therefore, it is important
to reach an early diagnosis that permits the rapid
identification of infected children [3,4].
Two rapid techniques are available for the
diagnosis of infection by RSV, based on either
virus antigen detection in respiratory secretions
(enzyme immunoassay) or direct immunofluores-
cence [5]. Virus isolation in cell culture is consid-
ered to be the standard against which all new
techniques for detection and isolation of RSV
should be compared [6,7]. However, the shell vial
culture method has been shown to be more sensi-
tive and rapid than classic cell culture, suggesting
that this method may substitute for culture in the
study of epidemic outbreaks of bronchiolitis
caused by RSV [8,9]. This article describes a
prospective study of the efficacy of a rapid antigen
detectionmethod, in comparisonwith the shell vial
method of isolation in culture, for the detection of
RSV in nasopharyngeal aspirates from children
with a clinical diagnosis of bronchiolitis.
MATERIALS AND METHODS
This was a prospective study that included all paediatric
patients (aged < 14 years) who attended the emergency
department of University Hospital Son Dureta (Palma de
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Mallorca, Spain) in the November–March period for seven
consecutive years (1995–2002). Nasopharyngeal aspirates from
these patients were inoculated in liquid transport medium
(Earle’s minimum essential medium (MEM) with bovine
serum albumin 0.5% w ⁄v) and sent as soon as possible to
the virology laboratory. On arrival at the laboratory, the
nasopharyngeal samples were diluted in 3 mL of sterile saline
solution. The rapid antigen detection method, which involved
an enzyme immunomembrane filter assay (ColorPAC, Directi-
gen RSV; Becton Dickinson, Franklin Lakes, NJ, USA) was
performed with 250 lL of the sample, following the manu-
facturer’s instructions both for the preparation of the sample
and for reading the results. Samples giving indeterminate
results were retested according to the manufacturer’s instruc-
tions.
For the shell vial technique, 200 lL of the same sample
was inoculated into two Hep-2 vials (Vircell; Ingelheim
Diagnostica, Madrid, Spain), centrifuged at 700 g for 45 min,
and incubated at 36C for 60 min; after this, the supernatant
was discarded. One millilitre of maintenance medium (MEM
containing fetal bovine serum 1% v ⁄v) was added to each
sample, and the vials were incubated at 36C for 2 days.
After incubation, the monolayers were stained with anti-RSV
(Monofluokit RSV; Bio-Rad, Madrid, Spain) and viewed at
· 200 and · 400 magnification with a fluorescence micro-
scope.
Enzyme immunoassay-positive, culture-negative samples
(stored at 4C) were re-inoculated into vials of Hep-2, MDCK,
LLC-MK2 and MRC-5 cell lines and incubated for 3 days at
36C, after which the monolayers were stained with anti-RSV,
anti-adenovirus, anti-influenza virus, anti-parainfluenza 1, 2
and 3 (Monofluokit; Bio-Rad) and anti-enterovirus (Dako, Ely,
UK) monoclonal antibodies.
For statistical analysis, all positive cultures were considered
to be true positives. Samples that were ColorPAC-positive, but
from which viruses other than RSV were isolated, were
considered to be probable false-positives. Samples that
were ColorPAC-positive and culture-negative for other viruses
were submitted to a direct immunofluorescence assay (DFA)
against RSV (Monofluokit RSV; Bio-Rad). Negative shell vial
cultures were considered to be false-negative if they were
ColorPAC-positive, culture-negative and DFA-negative.
Sensitivity, specificity and positive and negative predictive
values for the ColorPAC assay were calculated by comparison
with isolation of RSV by shell vial culture. Testing efficiency
was defined as the total number of correctly assigned testing
values (true positives and true negatives for each assay)
divided by the number of specimens tested. Statistical analysis
was carried out by performing Student’s t-test on paired data.
All p values were two-tailed and were considered significant if
< 0.05 [10].
RESULTS
Only samples received during the months of
greatest incidence of RSV infection (November–
March), for seven consecutive years,were included
in this prospective study. In total, 4950 samples
were analysed, and 1660 (33.5%) were positive for
RSV. The ColorPAC assay and shell vial culture
were positive for 1277 (76.8%) samples; for 300
(18.1%) samples, only the shell vial culture was
positive; and for 83 (4.9%) samples, only the
ColorPAC assay was positive. Thus, comparing
the ColorPAC assay with shell vial culture, the
ColorPAC assay had a sensitivity of 80.9%, a
specificity of 97.5%, a positive predictive value of
93.8%, a negative predictive value of 91.6%, and a
testing efficiency value of 92.2%.
The 83 samples considered initially to be
false-positive ColorPAC results represented
4.9% of the RSV-positive samples and 1.6% of
all samples. Of these, 71 (85.6%) were ultimately
considered to be shell vial culture false-negat-
ives, because no other virus could be isolated
and the DFA was positive. These samples
represented 4.2% of the RSV-positive samples
and 1.4% of all samples. With 12 (14.4%)
samples, it was possible to isolate a virus after
re-inoculating the shell vial cultures (nine influ-
enza viruses (six influenza B and three influenza
A), two adenovirus, and one parainfluenza
virus). These samples were considered to be
true ColorPAC false-positives, as the DFA was
also negative, and represented 0.7% of RSV-
positive samples and 0.25% of all samples.
In order to analyse the efficacy of the ColorPAC
assay, the samples were first grouped cumula-
tively according to individual months (Table 1).
The only significant differences were between the
percentages for positive results (p < 0.05) and
sensitivity (p 0.051) for RSV detection in the
month of November and the average values
detected in all the samples studied. Non-signifi-
cant differences were detected in the values for
specificity, positive predictive value, negative
predictive value and testing efficiency value in
the different months studied (Fig. 1).
In a second analysis, the clinical samples were
grouped according to annual epidemic periods
(Table 2). A statistical difference in the percentage
of positive results, with respect to the overall
percentages obtained, was observed only in the
epidemic periods of 1995 and 1996 (Fig. 2). No
significant differences were detected between the
epidemic periods over the entire length of the
study.
Compared with the ColorPAC assay, shell vial
culture had a sensitivity of 95.8% and a specificity
of 100%, since the ColorPAC assay gave true-
positive results for 71 samples that yielded no
growth in shell vial culture.
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DISCUSSION
The annual epidemics of bronchiolitis caused by
RSV affect c. 10–20% of the population aged
< 2 years. Of this group, nearly 20% require
hospitalisation because of the severity of the
disease and the young age of the patients [1,2].
As RSV is easily disseminated and transmitted, it
is essential to obtain a rapid aetiological diagnosis
of this infection in order to allocate patients to
appropriate hospital zones or isolation wards.
The aim is to avoid an outbreak of RSV nosoco-
mial infections, which, in general, have a more
severe clinical outcome than community-acquired
infections [3,4].
Of the different rapid diagnostic methods
available for RSV, enzyme immunoassay systems
provide high sensitivity and specificity, as well as
being appropriate for routine use, with results
available in < 15 min [5,10,11]. The present pros-
pective study of the ColorPAC assay demonstra-
ted acceptable levels of sensitivity (80.9%) and
specificity (97.5%). Only samples received during
the months considered to have the highest rate of
RSV infections (November–March) were included
in the study, since the screening methods used
could display significant variations in efficacy
according to the prevalence of the infection under
consideration [11–13]. Overall, the percentages
observed were higher than those obtained (sensi-
tivity 62.5% and specificity 91.8%) in a previous
study, carried out with a lower number of
samples in the period 1995–1996 [14]. They were
also higher than those reported by some other
research groups, ranging from 57% [15] to 76%
[16], although some authors have reported sensi-
tivity percentages close to 98% [17–20].
The ColorPAC assay was positive and the shell
vial culture was negative in 83 (5%) samples;
these were initially considered to be probable
false-positives of the antigen detection system.
This percentage was lower than that observed
(7.7%) in our previous study [14], but was similar
to that reported (4.8%) by Ribes et al. [20]. On
re-inoculation of these samples, a virus other than
RSV was isolated in 12 (14.4%) cases. Therefore,
only these samples should be considered as
Table 1. Monthly results obtained
during the prospective study period
(1995–2002) Month Total
No. (%)
RSV-positive
Test
sensitivity
(%)
Test
specificity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Testing
efficiency
value
November 509 59 (11.5) 67.9 98.6 85.7 96.3 95.4
December 1077 438 (40.6) 78.1 98.1 96.5 87.2 90.2
January 1350 565 (41.8) 83.2 98.6 97.6 89.4 92.2
February 1179 412 (34.9) 81.4 96.2 91.2 91.5 91.4
March 835 186 (22.5) 83.9 96.4 85.0 96.1 94.0
Total 4950 1660 (33.5) 80.9 97.5 93.8 91.6 92.2
Fig. 1. Comparison between the percentage of RSV-posit-
ive samples (solid bars) and sensitivity (open bars) of the
ColorPAC assay in each month during the epidemic
periods.
Table 2. Overall results obtained
in the prospective study period
(1995–2002) Period Total
No. (%)
RSV-positive
Test
sensitivity
(%)
Test
specificity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Testing
efficiency
value (%)
1995–1996 373 184 (49.3) 82.3 98.4 98.0 85.5 90.6
1996–1997 554 224 (40.6) 82.0 94.8 90.3 89.8 89.8
1997–1998 504 170 (33.7) 81.5 99.4 98.5 91.5 93.4
1998–1999 596 219 (36.7) 78.4 96.1 91.4 89.5 90.1
1999–2000 1027 317 (30.8) 83.1 96.4 90.2 93.5 92.6
2000–2001 982 346 (35.2) 77.8 97.3 93.7 89.7 90.8
2001–2002 914 200 (21.8) 82.8 99.7 98.7 95.4 96.1
Total 4950 1660 (33.5) 80.9 97.5 93.8 91.6 92.2
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probable false-positives, because no RSV was
isolated following re-inoculation. Thus, the Col-
orPAC method was considered to yield probable
false-positives with only 0.7% of all samples
positive for RSV.
With 71 ColorPAC-positive samples, it was not
possible to isolate any virus following re-inocula-
tion, but the DFA was also positive. For these
samples, it is possible that a delay in inoculation
or instability of RSV prevented its growth in cell
culture [8,10,14]. The comparison of the shell vial
culture with the ColorPAC assay gave the latter a
sensitivity of 95.8%, which is far higher than the
values reported previously of 73–89% [8,13,14,18].
However, these percentages depend on the pop-
ulation (age and social status) and season of the
year studied (months with higher prevalence), as
well as the prevalence (rate) of infection during
the period studied [1,2].
Because of the variability that these conditions
impose on the results of antigen detection meth-
ods for most virus respiratory infections [1,2], the
present study analysed the efficacy of ColorPAC
in each of the epidemic months and in each
epidemic period separately. The percentage of
positive RSV samples varied according the month
studied. The highest percentages (40.6% and
41.8%) were found in the classic epidemic months
(December and January). Only the month of
November had a positivity percentage lower than
the average (33.5%) for the 5 months studied.
Despite this difference, only a small, non-signfi-
cant difference was observed in the sensitivity of
the ColorPAC assay for the month with the lowest
rate of infection (i.e., November). When these data
are combined, it can be seen that the ColorPAC
assay had a stable, homogeneous efficacy, and did
not appear to be excessively influenced by the rate
of infection observed individually in each of the
months studied.
The efficacy analysis of the ColorPAC assay in
each of the epidemic periods showed a significant
difference in the positivity percentage (49.3%) for
the period 1995–1996 compared to the average
(33.5%) obtained over the entire study period.
Nevertheless, hardly any difference was observed
in the different parameters that indicated the true
efficacy of the ColorPAC assay, either in this or
the following periods. Thus, the ColorPAC assay
displayed statistical stability over the seven epi-
demic periods, with positivity percentages oscil-
lating between 21.8% and 49.3%.
In summary, the commercially available Color-
PAC assay had sensitivity and specificity percent-
ages which were stable and independent of the
annual rate of infection by RSV. It therefore seems
that this assay is an acceptable, simple and rapid
method for use in the antigenic detection of RSV,
especially during the winter epidemic months.
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